#4 - Biopharmaceutical Stocks (NYSE:LLY)
Some tried-and-true investment advice involves skating to where the puck is going. As many investors have seen, GLP-1 drugs are clearly where the money is going. As more research is collected, patients are becoming more comfortable with these drugs as a treatment for Type-2 diabetes and, increasingly, for weight loss.
That means that there is likely to be a long runway for companies like Eli Lilly & Co. (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO). These are the two leaders, and although more competition is coming, these two will continue to have a first-mover advantage.
Oncology is another area showing promise for biopharmaceutical investors in 2025. While a cure remains elusive, there’s more hope than ever before. Merck & Co. (NYSE: MRK) is well-known for its cancer drug, Keytruda. But the company also has a deep pipeline of oncology drugs and recently purchased Daiichi Sankyo for $5.5 billion. This gives Merck the right to co-develop three of the Japanese company’s antibody-drug conjugates.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More - Current Price
- $748.01
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $1,007.94 (34.8% Upside)
